Tassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., . . . Ravaggi, A. (2017). FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. BMC.
Chicago Style (17th ed.) CitationTassi, Renata A., et al. FOXM1 Expression Is Significantly Associated with Chemotherapy Resistance and Adverse Prognosis in Non-serous Epithelial Ovarian Cancer Patients. BMC, 2017.
MLA (9th ed.) CitationTassi, Renata A., et al. FOXM1 Expression Is Significantly Associated with Chemotherapy Resistance and Adverse Prognosis in Non-serous Epithelial Ovarian Cancer Patients. BMC, 2017.
Warning: These citations may not always be 100% accurate.